AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6230296 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 30
Study 6230296 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not treated with Thymostimulin or untreated)
Number of subjects: 30
Study 31257435 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention targeting health professionals' and patients' behaviour regarding antibiotic use.
Number of subjects: 309
Study 29968556 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular diagnosis of samples
Number of subjects: 169
Study 29968556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of pfhrp2 exon-2
Number of subjects: 169
Study 29968556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitope mapping analysis
Number of subjects: 169
Study 27113166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10μg Hep-KSC
Number of subjects: 1731
Study 27113166 — intervention group
Group type: COMPARATOR
Intervention: 10μg Engerix-B
Number of subjects: 1731
Study 27113166 — intervention group
Group type: COMPARATOR
Intervention: 5μg Hep-KSC
Number of subjects: 1731
Study 27113166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10μg Hep-KSC (PM Group)
Number of subjects: 1731
Study 27113166 — intervention group
Group type: COMPARATOR
Intervention: 10μg Engerix-B (PM Group)
Number of subjects: 1731
Study 23794225 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (administered once every 6 months for 36 months)
Number of subjects: 99
Study 23794225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 23794225 — intervention group
Group type: COMPARATOR
Intervention: Denosumab vs Placebo
Number of subjects: 99
Study 22835804 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS+CM (Comprehensive Health Enhancement Support System + monthly nurse case management via phone)
Number of subjects: 301
Study 22835804 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS+CM
Number of subjects: 301
Study 22835804 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual plus asthma information)
Number of subjects: 301
Study 20427350 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT), cisplatin 40 mg/m² weekly for seven doses plus RT
Number of subjects: 153
Study 20427350 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (RT), 70 Gy/35 fractions over 7 weeks
Number of subjects: 153
Study 20427350 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 153
Study 20427350 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (RT)
Number of subjects: 153
Study 17905018 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐hyoscyamine 0.5 mg
Number of subjects: 200
Study 17905018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16415698 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 31
Study 16415698 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 31
Study 12814710 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 5963
Study 10817552 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra 30 mg/day
Number of subjects: 472
Study 10817552 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra 75 mg/day
Number of subjects: 472
Study 10817552 — intervention group
Group type: EXPERIMENTAL
Intervention: All IL-1Ra treatment groups combined
Number of subjects: 472
Study 10817552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 8784014 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after operation
Number of subjects: 132
Study 8784014 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiation after operation
Number of subjects: 132
Study 8784014 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 132
Study 8784014 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiation
Number of subjects: 132
Study 8784014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 132
Study 1617046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 3
Study 1617046 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 3
Study 1617046 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 3
Study 6228370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg orally 2 h before exercise
Number of subjects: 10
Study 6228370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.216 mg by inhalation 30 min before exercise
Number of subjects: 10
Study 6228370 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 10
Study 31435653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel (UBS)
Number of subjects: 190
Study 31435653 — intervention group
Group type: COMPARATOR
Intervention: High-speed rotatory drill
Number of subjects: 190
Study 31781698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 42
Study 31781698 — intervention group
Group type: COMPARATOR
Intervention: Conventional Loading (CL)
Number of subjects: 42
Study 28743370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group (50Hz, 0.2N or 20g applied on the buccal surface of maxillary canine)
Number of subjects: 13
Study 28743370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration)
Number of subjects: 13
Study 28743370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group
Number of subjects: 13
Study 26171639 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual expression
Number of subjects: 21
Study 26171639 — intervention group
Group type: COMPARATOR
Intervention: Electric pump
Number of subjects: 21
Study 23635884 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste
Number of subjects: 622
Study 23635884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gel (CHX)
Number of subjects: 622
Study 23635884 — intervention group
Group type: COMPARATOR
Intervention: No product (study control [SC])
Number of subjects: 622
Study 21998174 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term recall of condom use (last sex act)
Number of subjects: 1000
Study 21998174 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-term recall of condom use (over the past month and year)
Number of subjects: 1000
Study 21998174 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use with clients
Number of subjects: 1000
Study 21998174 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use with non-paying partners
Number of subjects: 1000
Study 18330809 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis (Thämert Osteomed) with paravertebral/lumbosacral air chamber pads
Number of subjects: 40
Study 18330809 — intervention group
Group type: COMPARATOR
Intervention: The same orthosis without air chamber pads
Number of subjects: 40
Study 18330809 — intervention group
Group type: COMPARATOR
Intervention: Placebo body stocking
Number of subjects: 40
Study 16989497 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine (10-15 mg)
Number of subjects: 131
Study 16989497 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (5-10 mg)
Number of subjects: 131
Study 15284828 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d, 3 cycles
Number of subjects: 186
Study 15284828 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d, 6 cycles
Number of subjects: 186
Study 15284828 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d, 3 cycles
Number of subjects: 186
Study 10758445 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)
Number of subjects: 0
Study 10758445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)
Number of subjects: 0
Study 10758445 — intervention group
Group type: COMPARATOR
Intervention: Control group (only epidural morphine)
Number of subjects: 0
Study 9172193 — intervention group
Group type: EXPERIMENTAL
Intervention: High contextual interference (random practice)
Number of subjects: 48
Study 9172193 — intervention group
Group type: COMPARATOR
Intervention: Low contextual interference (blocked practice)
Number of subjects: 48
Study 1304175 — intervention group
Group type: EXPERIMENTAL
Intervention: .717% fluoride solution
Number of subjects: 30
Study 1304175 — intervention group
Group type: EXPERIMENTAL
Intervention: .04% stannous fluoride gel (Gel‐Kam)
Number of subjects: 30
Study 1304175 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study 2413097 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg of slow release oxprenolol
Number of subjects: 736
Study 2413097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 736
Study 30786849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study 29771607 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg movement (PLM) at various joint angle ROMs (0°‐50°, 50°‐100°, 0°‐100°) and angular velocities (fast: 200°/s, slow: 100°/s)
Number of subjects: 12
Study 27598024 — intervention group
Group type: EXPERIMENTAL
Intervention: FGLS group
Number of subjects: 110
Study 27598024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 24629559 — intervention group
Group type: EXPERIMENTAL
Intervention: Small store interventions
Number of subjects: 0
Study 23079770 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (10 g daily)
Number of subjects: 1741
Study 23079770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 20732581 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 14
Study 20732581 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 14
Study 17593237 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp30 (once daily)
Number of subjects: 192
Study 17593237 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp30 (twice daily)
Number of subjects: 192
Study 17593237 — intervention group
Group type: COMPARATOR
Intervention: OAD-only
Number of subjects: 192
Study 17593237 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp30 (o.d. and b.i.d. pooled)
Number of subjects: 192
Study 16360963 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 80
Study 12215234 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (2.5 mg)
Number of subjects: 20
Study 12215234 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (2.0 mg)
Number of subjects: 20
Study 9857924 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.1 IU x kg(‐1) week(‐1) for 1 week, then 0.25 IU x kg(‐1) week(‐1) for 3 months)
Number of subjects: 22
Study 9857924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 22
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2.5 mg
Number of subjects: 97
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5.0 mg
Number of subjects: 97
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 10 mg
Number of subjects: 97
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (optimal dose)
Number of subjects: 97
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 97
Study 7611760 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory findings
Number of subjects: 97
Study 2229525 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 20
Study 2229525 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 20
Study 356254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (0.20 mg/puff)
Number of subjects: 15
Study 356254 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg/puff)
Number of subjects: 15
Study 30902431 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guidance system (VERION) and intraoperative aberrometry (ORA System with VerifEye+) with femtosecond laser-assisted cataract surgery
Number of subjects: 78
Study 30902431 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's standard of care
Number of subjects: 78
Study 28100669 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine-calcitonin-fentanyl (BCF)
Number of subjects: 60
Study 28100669 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-fentanyl (BF)
Number of subjects: 60
Study 25429095 — intervention group
Group type: EXPERIMENTAL
Intervention: HeO2 (21% O2:balance He)
Number of subjects: 21
Study 25429095 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 21
Study 25429095 — intervention group
Group type: EXPERIMENTAL
Intervention: HeO2
Number of subjects: 21
Study 24951357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (80 units in 500ml of 0.9% normal saline at 2ml/min)
Number of subjects: 86
Study 24951357 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 86
Study 22300008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital use of tissue plasminogen activator in an ambulance with a stroke emergency mobile unit
Number of subjects: 0
Study 22300008 — intervention group
Group type: COMPARATOR
Intervention: Regular care (without stroke emergency mobile unit)
Number of subjects: 0
Study 22300008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital use of tissue plasminogen activator
Number of subjects: 0
Study 22300008 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 0
Study 19008237 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk (HR) group for OSA
Number of subjects: 178
Study 19008237 — intervention group
Group type: COMPARATOR
Intervention: Low risk (LR) group for OSA
Number of subjects: 178
Study 17502411 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 0
Study 17502411 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study 16364832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus LBK‐16H fermented milk (150 mL twice daily for 10 weeks)
Number of subjects: 94
Study 16364832 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 94
Study 16364832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus LBK‐16H fermented milk
Number of subjects: 94
Study 11942450 — intervention group
Group type: EXPERIMENTAL
Intervention: BabyCheck
Number of subjects: 497
Study 9794010 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar and bipolar patients with recurrent episodes
Number of subjects: 204
Study 9794010 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar and bipolar patients
Number of subjects: 204
Study 9794010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent episodes
Number of subjects: 204
Study 9794010 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 204
Study 7649139 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min voluntary exercise at 30% of maximal voluntary contraction
Number of subjects: 10
Study 7649139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min of 10 Hz stimulation after exercise
Number of subjects: 10
Study 2664340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 2664340 — intervention group
Group type: COMPARATOR
Intervention: Finnish analogue of prazosin
Number of subjects: 0
Study 1104344 — intervention group
Group type: EXPERIMENTAL
Intervention: KAVOSAN
Number of subjects: 43
Study 1104344 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 43
Study 30999969 — intervention group
Group type: EXPERIMENTAL
Intervention: HandScan-guided treatment aimed at 'HandScan remission' (HandScan arm)
Number of subjects: 122
Study 30999969 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided treatment aimed at ACR/EULAR 2011 Boolean remission (DAS arm)
Number of subjects: 122
Study 30999969 — intervention group
Group type: EXPERIMENTAL
Intervention: HandScan-guided treatment
Number of subjects: 122
Study 30999969 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided treatment
Number of subjects: 122
Study 28393444 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique III: intermittent SVC clamping
Number of subjects: 75
Study 28393444 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique II: superior vena cava (SVC) cannulation
Number of subjects: 75
Study 28393444 — intervention group
Group type: COMPARATOR
Intervention: All techniques of BDG
Number of subjects: 75
Study 26099869 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 18
Study 26099869 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 18
Study 24206099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.0-1.4 mg/kg/day)
Number of subjects: 209
Study 24206099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 21681159 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm Water (WW) at 38 °C for 30 minutes
Number of subjects: 60
Study 21681159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water (CW) at 20 °C for 30 minutes
Number of subjects: 60
Study 21681159 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO) with no intervention
Number of subjects: 60
Study 19436141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet V (increased vegetable consumption)
Number of subjects: 57
Study 19436141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased cereal consumption)
Number of subjects: 57
Study 19436141 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 16923002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar, lumenless, catheter-delivered pacemaker lead (Model 3830)
Number of subjects: 338
Study 15168891 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins plus creatine (amount equal to twice daily creatinine excretion) for four weeks
Number of subjects: 0
Study 15168891 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins (control group) for four weeks
Number of subjects: 0
Study 14674495 — intervention group
Group type: EXPERIMENTAL
Intervention: EC 40 (EC)
Number of subjects: 22
Study 14674495 — intervention group
Group type: COMPARATOR
Intervention: Cervitec (CE)
Number of subjects: 22
Study 14674495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime and Bond NT (PB)
Number of subjects: 22
Study 14674495 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal & Protect (SP)
Number of subjects: 22
Study 10468866 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐3 10 microgram/kg/d
Number of subjects: 198
Study 10468866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198
Study 10468866 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐3
Number of subjects: 198
Study 8645788 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily for 14 days)
Number of subjects: 9
Study 8645788 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily for 7 or 14 days)
Number of subjects: 9
Study 2083857 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution VI (glucose 80, sodium 30, potassium 20 mmol/l; 177 mOsm/kg)
Number of subjects: 0
Study 2083857 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution II (WHO oral rehydration solution; glucose 111, sodium 90, bicarbonate 30, potassium 20; 308 mOsm/kg)
Number of subjects: 0
Study 2083857 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution IV (glucose 111, sodium 60, potassium 20 mmol/l; 260 mOsm/kg)
Number of subjects: 0
Study 2083857 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution III (hypertonic commercial oral rehydration solution; glucose 188, sodium 50, bicarbonate 20, potassium 20 mmol/l; 335 mOsm/kg)
Number of subjects: 0
Study 2083857 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution V (glucose 80, sodium 60, potassium 20 mmol/l; 219 mOsm/kg)
Number of subjects: 0
Study 2083857 — intervention group
Group type: COMPARATOR
Intervention: Solution I (standard cleansing solution; sodium 125, potassium 10, bicarbonate 20, sulphate 40, mannitol 80 mmol/l; 275 mOsm/kg)
Number of subjects: 0
Study 6985775 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal staples
Number of subjects: 100
Study 6985775 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 100
Study 27825893 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg ⋅ kg‐1 ⋅ d‐1 intravenous infusion for 48 hours)
Number of subjects: 0
Study 27825893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27825893 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 0
Study 26477635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802
Study 26477635 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 802
Study 23635860 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol sodium (DQS) eye drops
Number of subjects: 56
Study 23635860 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 56
Study 22136774 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral gastroplasty (TOGA)
Number of subjects: 67
Study 18637106 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head neutral-gaze down'
Number of subjects: 18
Study 18637106 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head flexed-gaze down'
Number of subjects: 18
Study 18637106 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head neutral-gaze forward'
Number of subjects: 18
Study 18637106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal spectacles with 'head neutral-gaze down'
Number of subjects: 18
Study 18637106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal spectacles with 'head flexed-gaze down'
Number of subjects: 18